BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38504659)

  • 21. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT).
    Heetman JG; Lavalaye J; Polm PD; Soeterik TFW; Wever L; Paulino Pereira LJ; van der Hoeven EJRJ; van Melick HHE; van den Bergh RCN
    Eur Urol Oncol; 2024 Apr; 7(2):204-210. PubMed ID: 37296065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study.
    Krausewitz P; Fostitsch D; Weiten R; Kluemper N; Stein J; Luetkens J; Kristiansen G; Ellinger J; Ritter M
    World J Urol; 2023 Jan; 41(1):19-25. PubMed ID: 36477403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy.
    Ruan M; Wang H; Li X; Song G
    Abdom Radiol (NY); 2023 Jun; 48(6):2139-2147. PubMed ID: 37036488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of
    Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
    Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies.
    Maxeiner A; Nest AM; Stephan C; Cash H; Baur ADJ; Fischer T; Kilic E; Piper SK; Nowak CP; Busch J; Miller K; Mang J
    Urol Int; 2020; 104(3-4):205-213. PubMed ID: 31801153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Utility of
    Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
    Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?
    Günzel K; Magheli A; Busch J; Baco E; Cash H; Heinrich S; Edler D; Schostak M; Borgmann H; Schlegel J; Hinz S
    Int Urol Nephrol; 2022 Oct; 54(10):2477-2483. PubMed ID: 35877030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
    Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
    Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
    Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38281891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of prostate cancer with
    Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
    World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current state of prostate-specific membrane antigen PET/CT imaging-targeted biopsy techniques for detection of clinically significant prostate cancer.
    Ma L; Zhang WC; Hao YX
    J Med Imaging Radiat Oncol; 2022 Sep; 66(6):776-780. PubMed ID: 34914195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
    Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
    Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection Rate of
    Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
    Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head-to-Head Comparison of
    Exterkate L; Hermsen R; Küsters-Vandevelde HVN; Prette JF; Baas DJH; Somford DM; van Basten JA
    Eur Urol Oncol; 2023 Dec; 6(6):574-581. PubMed ID: 37230883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additional value of magnetic resonance-targeted biopsies to standard transrectal ultrasound-guided biopsies for detection of clinically significant prostate cancer.
    von Below C; Wassberg C; Norberg M; Tolf A; Kullberg J; Ladjevardi S; Häggman M; Bill Axelson A; Ahlström H
    Scand J Urol; 2017 Apr; 51(2):107-113. PubMed ID: 28635568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between Prostate Cancer Positive Cores and 68Ga-PSMA Distribution in Prostate Gland.
    Çankaya S; Caylan AE; Aydin F; Uçar M; Kutlu Ö
    Urol Int; 2024; 108(1):65-72. PubMed ID: 38016433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
    Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
    Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.